Key result
Intravenous prenalterol increased cardiac index (from 1.8 to 2.1 L/min/m2) and left ventricular ejection fraction (from 22% to 28%) in patients with severe chronic congestive cardiac failure.
Why the study?
Does intravenous prenalterol improve rest and exercise haemodynamics in patients with chronic congestive cardiac failure and left ventricular dysfunction?
Observational (n=15)
Does intravenous prenalterol improve rest and exercise haemodynamics in patients with chronic congestive cardiac failure and left ventricular dysfunction?
Intravenous prenalterol acutely improves cardiac index and ejection fraction in patients with severe heart failure without significant arrhythmogenic effects.
May support acute use in refractory HF; hypothesis-generating for exercise hemodynamics and outcomes.
?The cardiovascular effects of the cardioselective beta, agonist prenalterol have been studied in nine patients with severe chronic congestive cardiac failure and in six patients with left ventricular dysfunction resulting from previous myocardial infarction. In the patients with cardiac failure intravenous prenalterol in a dosage of 1.5 microgram/kg bodyweight increased the cardiac index from 1.8 +/- 0.1 to 21.+/- 0.1 1/min per m2 and the left ventricular ejection fraction from 22 +/- 3 to 28 +/- 3%. There was a modest but significant increase in heart rate from 76 +/- 3 to 87 +/- 4 beats/min. Systemic vascular resistance fell from 2285 +/- 51 to 2041 +/- 534 dynes s-1 cm-5. On exercise, the left ventricular filling pressure fell from 33 +/- 6 to 26 +/- 3 and both cardiac index and stroke index increased by 13% and 16%, respectively. There was no significant change in heart rate or systemic blood pressure. In the patients with left ventricular dysfunction, coronary sinus blood flow increased from 107 +/- 11 to 133 +/- 12 ml/min but the increase in myocardial oxygen consumption was small and not significant (11.6 +/- 1.2 and 14.5 +/- 1.9 ml/min). In all patients there was no evidence that prenalterol was arrhythmogenic.
No takes yet. Share an insight, caveat, or question.
Tweddel et al. (1982) conducted an observational in Severe chronic congestive cardiac failure and left ventricular dysfunction (n=15). Prenalterol was evaluated on Rest and exercise haemodynamics (cardiac index, left ventricular ejection fraction). Intravenous prenalterol increased cardiac index (from 1.8 to 2.1 L/min/m2) and left ventricular ejection fraction (from 22% to 28%) in patients with severe chronic congestive cardiac failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: